Abstract
Background: Despite being considered as good prognostic acute myelogenous leukemia (AML), the long-term survival rate in core binding factor (CBF) AML leaves room for substantial improvement. Materials and Methods: We reviewed relevant English language literature related to treatment of CBF AML available in PubMed. Review also included meeting abstracts. Results: Multicycle high dose cytarabine in consolidation improves remission duration but larger groups report overall survival in the range of 40% to 50% at 5 years or longer. Conclusions: Concerted effort is needed toward improving outcomes in CBF AML through clinical trials and risk-adapted approach.
Original language | English (US) |
---|---|
Pages (from-to) | 153-158 |
Number of pages | 6 |
Journal | Clinical Lymphoma, Myeloma and Leukemia |
Volume | 13 |
Issue number | 2 |
DOIs | |
State | Published - Apr 2013 |
Externally published | Yes |
Keywords
- Chemotherapy
- High-dose cytarabine
- Inversion (16)
- Response
- Translocation (8;21)
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research